The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurometabolic Disorders Market Research Report 2024
Synopsis
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The global Neurometabolic Disorders market was valued at US$ 1254 million in 2023 and is anticipated to reach US$ 1706 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
This report aims to provide a comprehensive presentation of the global market for Neurometabolic Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurometabolic Disorders.
Report Scope
The Neurometabolic Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurometabolic Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurometabolic Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Segment by Application
Oral
Parenteral
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurometabolic Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The global Neurometabolic Disorders market was valued at US$ 1254 million in 2023 and is anticipated to reach US$ 1706 million by 2030, witnessing a CAGR of 4.5% during the forecast period 2024-2030.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
This report aims to provide a comprehensive presentation of the global market for Neurometabolic Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurometabolic Disorders.
Report Scope
The Neurometabolic Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurometabolic Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurometabolic Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Segment by Application
Oral
Parenteral
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurometabolic Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gaucher’s Disease
1.2.3 Fabry Disease
1.2.4 Pompe Disease
1.2.5 Mucopolysaccharidosis VI
1.2.6 Other
1.3 Market by Application
1.3.1 Global Neurometabolic Disorders Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oral
1.3.3 Parenteral
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurometabolic Disorders Market Perspective (2019-2030)
2.2 Neurometabolic Disorders Growth Trends by Region
2.2.1 Global Neurometabolic Disorders Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurometabolic Disorders Historic Market Size by Region (2019-2024)
2.2.3 Neurometabolic Disorders Forecasted Market Size by Region (2025-2030)
2.3 Neurometabolic Disorders Market Dynamics
2.3.1 Neurometabolic Disorders Industry Trends
2.3.2 Neurometabolic Disorders Market Drivers
2.3.3 Neurometabolic Disorders Market Challenges
2.3.4 Neurometabolic Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurometabolic Disorders Players by Revenue
3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2019-2024)
3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2019-2024)
3.2 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
3.4 Global Neurometabolic Disorders Market Concentration Ratio
3.4.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2023
3.5 Neurometabolic Disorders Key Players Head office and Area Served
3.6 Key Players Neurometabolic Disorders Product Solution and Service
3.7 Date of Enter into Neurometabolic Disorders Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurometabolic Disorders Breakdown Data by Type
4.1 Global Neurometabolic Disorders Historic Market Size by Type (2019-2024)
4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2025-2030)
5 Neurometabolic Disorders Breakdown Data by Application
5.1 Global Neurometabolic Disorders Historic Market Size by Application (2019-2024)
5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurometabolic Disorders Market Size (2019-2030)
6.2 North America Neurometabolic Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurometabolic Disorders Market Size by Country (2019-2024)
6.4 North America Neurometabolic Disorders Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurometabolic Disorders Market Size (2019-2030)
7.2 Europe Neurometabolic Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurometabolic Disorders Market Size by Country (2019-2024)
7.4 Europe Neurometabolic Disorders Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurometabolic Disorders Market Size (2019-2030)
8.2 Asia-Pacific Neurometabolic Disorders Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurometabolic Disorders Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurometabolic Disorders Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurometabolic Disorders Market Size (2019-2030)
9.2 Latin America Neurometabolic Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurometabolic Disorders Market Size by Country (2019-2024)
9.4 Latin America Neurometabolic Disorders Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurometabolic Disorders Market Size (2019-2030)
10.2 Middle East & Africa Neurometabolic Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurometabolic Disorders Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurometabolic Disorders Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amicus Therapeutics
11.1.1 Amicus Therapeutics Company Detail
11.1.2 Amicus Therapeutics Business Overview
11.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
11.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2019-2024)
11.1.5 Amicus Therapeutics Recent Development
11.2 ISU Abxis
11.2.1 ISU Abxis Company Detail
11.2.2 ISU Abxis Business Overview
11.2.3 ISU Abxis Neurometabolic Disorders Introduction
11.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2019-2024)
11.2.5 ISU Abxis Recent Development
11.3 JCR Pharmaceuticals
11.3.1 JCR Pharmaceuticals Company Detail
11.3.2 JCR Pharmaceuticals Business Overview
11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
11.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2019-2024)
11.3.5 JCR Pharmaceuticals Recent Development
11.4 Biosidus
11.4.1 Biosidus Company Detail
11.4.2 Biosidus Business Overview
11.4.3 Biosidus Neurometabolic Disorders Introduction
11.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2019-2024)
11.4.5 Biosidus Recent Development
11.5 Greenovation Biotech
11.5.1 Greenovation Biotech Company Detail
11.5.2 Greenovation Biotech Business Overview
11.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
11.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2019-2024)
11.5.5 Greenovation Biotech Recent Development
11.6 UAB Proforma
11.6.1 UAB Proforma Company Detail
11.6.2 UAB Proforma Business Overview
11.6.3 UAB Proforma Neurometabolic Disorders Introduction
11.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2019-2024)
11.6.5 UAB Proforma Recent Development
11.7 Dong-A Socio Group
11.7.1 Dong-A Socio Group Company Detail
11.7.2 Dong-A Socio Group Business Overview
11.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
11.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2019-2024)
11.7.5 Dong-A Socio Group Recent Development
11.8 ExSAR Corporation
11.8.1 ExSAR Corporation Company Detail
11.8.2 ExSAR Corporation Business Overview
11.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
11.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2019-2024)
11.8.5 ExSAR Corporation Recent Development
11.9 Lixte Biotechnology
11.9.1 Lixte Biotechnology Company Detail
11.9.2 Lixte Biotechnology Business Overview
11.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
11.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2019-2024)
11.9.5 Lixte Biotechnology Recent Development
11.10 Neuraltus Pharmaceuticals
11.10.1 Neuraltus Pharmaceuticals Company Detail
11.10.2 Neuraltus Pharmaceuticals Business Overview
11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
11.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2019-2024)
11.10.5 Neuraltus Pharmaceuticals Recent Development
11.11 Protalix
11.11.1 Protalix Company Detail
11.11.2 Protalix Business Overview
11.11.3 Protalix Neurometabolic Disorders Introduction
11.11.4 Protalix Revenue in Neurometabolic Disorders Business (2019-2024)
11.11.5 Protalix Recent Development
11.12 Pharming Group
11.12.1 Pharming Group Company Detail
11.12.2 Pharming Group Business Overview
11.12.3 Pharming Group Neurometabolic Disorders Introduction
11.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2019-2024)
11.12.5 Pharming Group Recent Development
11.13 Protalix BioTherapeutics
11.13.1 Protalix BioTherapeutics Company Detail
11.13.2 Protalix BioTherapeutics Business Overview
11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
11.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2019-2024)
11.13.5 Protalix BioTherapeutics Recent Development
11.14 Amicus
11.14.1 Amicus Company Detail
11.14.2 Amicus Business Overview
11.14.3 Amicus Neurometabolic Disorders Introduction
11.14.4 Amicus Revenue in Neurometabolic Disorders Business (2019-2024)
11.14.5 Amicus Recent Development
11.15 Biomarin
11.15.1 Biomarin Company Detail
11.15.2 Biomarin Business Overview
11.15.3 Biomarin Neurometabolic Disorders Introduction
11.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2019-2024)
11.15.5 Biomarin Recent Development
11.16 Genzyme
11.16.1 Genzyme Company Detail
11.16.2 Genzyme Business Overview
11.16.3 Genzyme Neurometabolic Disorders Introduction
11.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2019-2024)
11.16.5 Genzyme Recent Development
11.17 Shire
11.17.1 Shire Company Detail
11.17.2 Shire Business Overview
11.17.3 Shire Neurometabolic Disorders Introduction
11.17.4 Shire Revenue in Neurometabolic Disorders Business (2019-2024)
11.17.5 Shire Recent Development
11.18 Greencross
11.18.1 Greencross Company Detail
11.18.2 Greencross Business Overview
11.18.3 Greencross Neurometabolic Disorders Introduction
11.18.4 Greencross Revenue in Neurometabolic Disorders Business (2019-2024)
11.18.5 Greencross Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
